April 9, 2019
How to avoid mistakes during the filling process for cell and gene therapies and make sure that no human life is at risk
Autologous therapies are therapies that are derived from the patient and as such they exhibit certain specific requirements. The scope of such therapies differs greatly from what we usually see in the biopharma industry, and they require special handling and care. The quantities are much smaller than usual, but nonetheless they need to be shipped in a highly sterile and protected manner.
February 11, 2019
Why the CAR-T cell therapy can be a cause for human drama
According to information from the biopharmaceutical industry, the loss rate for CAR-T cell therapies is over 1%. This means that it can be assumed that currently only 99 out of 100 people receive a fully functional Car-T therapy. Read here!
February 8, 2019
CAR-T cell therapies: The therapy is slowly coming to the market – but does it also usefully reach the patient?
The National Health Service (NHS) of Great Britain, confirms the use of CAR-T Cell Therapy Kymriah on an 11-year-old leukaemia patient. However, it is not certain whether the vital therapy will make its way into society. Read it for yourself!
January 18, 2019
Storing and shipping frozen drug substances – why single-use systems are the optimal solution
Due to increased efficiency, flexibility and cost reduction, it has become standard practice to use integrated single use freeze-thaw systems with single use bags, tubing and connectors. Find out what the reasons for this are here!
December 6, 2018
FDA invites Single Use Support to present MITS.2D!
In November, Single Use Support GmbH Founder Johannes Kirchmaier presented the company newest development, the MITS.2D at the U.S. Food and Drug Administration (FDA) headquarters in Washington to more than 60 industry experts.
October 1, 2018
How a spontaneous idea turned into a “hack” benefitting a whole industry
As is the case with a number of developments, a spontaneous idea and the will to shake things up led to something big. Two young entrepreneurs from Tyrol, Austria, took on the challenge to “hack” the biopharma logistics process, or, in other words, to reinvent if not revolutionize it.
September 30, 2018
You want to know what an oyster has to do with higher returns in the biopharma industry?
It all starts with a grain of sand that by chance found its way into the oyster. The grain of sand is an annoyance; it poses a problem. The oyster feels disturbed so it deals with the intruder. But how does the oyster go about it – how does the oyster save its problem?